Gout is the most common inflammatory arthritis affecting 1-2% of the population. It is a very common problem presenting to ...

GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for ...

The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical--stage biotech company advancing RNA medicines, today announced that the U.S. Food and ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

A pattern of musculoskeletal injuries spurred researchers to conduct a study on whether using the popular weight-loss and diabetes drugs increased a person’s risk of other health conditions.

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

Lorraine Wylie on why feet can a reveal a lot about an individual’s state of health ...

GLP-1 receptor agonist use was linked to a significantly higher risk for osteoporosis, gout, and osteomalacia over 5 years.

GLP-1 receptor agonists appear to be associated with an increased risk for osteoporosis and other orthopedic conditions.